This newsletter presents you the following key sessions:
1. Podcast with dr. Kai Keen Shiu about the phase III randomized study of pembrolizumab versus
chemotherapy for patients with microsatellite-instability-high advanced colorectal cancer
2. Adjuvant S-1 plus docetaxel superior to S-1 monotherapy after a curative resection of stage III
gastric cancer
3. Impact of neoadjuvant therapies on the risk for perioperative complications in patients with
advanced thoracic oesophageal cancer
4. Trifluridine/tipiracil provides the greatest clinical benefit when used in the third line treatment
of patients with metastatic gastric cancer
5. The FGFR-selective tyrosine kinase inhibitor infigratinib shows promising efficacy in patients
advanced cholangiocarcinoma harbouring FGFR2 alterations
